Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AXAL

- PMLiVE

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

- PMLiVE

Is our health at risk by delaying Dr appointments?

It’s Cervical Screening Awareness week 10-16 June, so now is the perfect time to check when your last appointment was.

Page & Page and Partners

- PMLiVE

Advaxis shaken by another FDA hold on cervical cancer vaccine

Suspends enrolment into pivotal phase 3 trial

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

EU flag

EMA launches review of cervical cancer vaccine safety

Regulator assessing possible side effects of pain and arrhythmia in girls using the treatments

- PMLiVE

Avastin approved for cervical cancer in EU

Was approved for the same indication in the US last summer

- PMLiVE

Charity launches #SmearForSmear campaign

Jo's Cervical Cancer Trust aims to raise awareness of cancer screening

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

New York health department in HPV drive

New campaign will highlight the cancer-prevention benefits of the HPV vaccine

- PMLiVE

Avastin gets US green light for late-stage cervical cancer

Fifth oncology indication for Roche’s medicine

- PMLiVE

AstraZeneca steps up cancer immunotherapy research

MedImmune unit will study anti-PD1 drug in combination with Advaxis’ cervical cancer vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links